|
Subsidiaries and affiliates
Biofrontera AG is establishing a specialty pharmaceutical business for research and development in dermatology and inflammation. The company’s state-of-the-art laboratory facilities in Leverkusen, Germany, are modern and fully-equipped with sufficient space for projected growth and market expansion. Biofrontera’s specific expertise lies in the characterization of the pharmacological properties of drug candidates in vitro and in vivo. Biofrontera’s goal is to build a specialty pharmaceutical company with wholly owned products, initially for dermatologic applications. In the future, other pharmaceuticals for larger markets will result from Biofrontera’s in-house research. In addition, Biofrontera AG holds a wholly-owned subsidiary, Biofrontera Pharmaceuticals GmbH. Biofrontera Pharmaceuticals GmbH has three drugs in pre-clinical and clinical development. Two drugs are in phase II trials; the leading compound is expected to enter the market in 2007/08. Click here to get the latest Biofrontera Bond update. Trace Genetics is a modern DNA-testing laboratory committed to designing innovative, premiere services and providing optimal test results. The company specializes in genetic identity DNA analysis with expertise in ancestry genealogy, forensics, molecular diagnostics and population genetics. Trace Genetics™ has been a leader in its continued effort to pioneer new methods to set new industry standards for reliability and service. Co-founders Ripan S. Malhi and Jason Eshleman have over a decade of DNA identification experience and are considered industry leaders. They are two of only a handful of researchers worldwide considered to be experts in ancient DNA analysis. They were chosen to be part of the groundbreaking Kennewick Man research team for the US Department of the Interior. Both have worked extensively with the genetic genealogies of Native American peoples. In July 2005, Trace Genetics™ was acquired by DNAPrint Genomics Inc. |
